BioNTech (BNTX) Stock
Key stats
- Market cap
- $21.73B
- Price / Earnings ratio
- -13.1x
- EPS (TTM)
- -$6.63
- Volume
- Loading
- 52-week high
- $124.00
- 52-week low
- $79.52
- EPS vs analyst estimate
- -118.7%Q3 FY25 · -$0.14 vs $0.75
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with BNTX
Recent news
BioNTech Q3 Earnings Call Highlights
BioNTech Q3 Earnings Call Highlights
BNTX
Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next
Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next
BNTX
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
BNTX
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
BNTXNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 44.02
- MACD 12/26/9
- -1.81
- EMA 9 of MACD
- -2.08
- MACD histogram
- 0.27
- SMA 50
- $93.80
- Price below SMA 50
- EMA 50
- $92.15
- Price below EMA 50
- SMA 200
- $96.05
- Price below SMA 200
- EMA 200
- $95.93
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.22 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
BioNTech Q3 Earnings Call Highlights
BioNTech Q3 Earnings Call Highlights
BNTXStocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next
Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next
BNTXModerna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
BNTXModerna's Rally May Have Run Out of Steam. Here's What to Watch Next
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next
BNTX
Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
BNTX
MRNA Stock’s Vaccine Rally Cracks As Worst Week In 3 Months Looms — Analyst Calls It A ‘Do-Not-Trade’ Over Wild Swings
MRNA Stock’s Vaccine Rally Cracks As Worst Week In 3 Months Looms — Analyst Calls It A ‘Do-Not-Trade’ Over Wild Swings
BNTX
Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher
Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher
BNTX
BioNTech, Gilead to test drug combination in advanced breast cancer trial
BioNTech, Gilead to test drug combination in advanced breast cancer trial
BNTX
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?
Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?
BNTX
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
BNTXNews tone: automated (AI) classification of the article's content, not a price prediction.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Ugur Sahin M.D. | Co-Founder, CEO & Chair of the Management Board | 1965 |
| Mr. Ramon Zapata-Gomez | CFO & Member of Management Board | 1974 |
| Dr. Sierk Pötting Ph.D. | MD, COO & Member of Management Board | 1973 |
| Dr. Ozlem Tureci M.D. | Co-Founder, Chief Medical Officer & Member of Management Board | 1967 |
| Dr. James Timothy Patrick Ryan Ph.D. | Chief Legal & Business Officer and Member of the Management Board | 1975 |
| Ms. Annemarie Hanekamp | Chief Commercial Officer & Member of Management Board | 1980 |
| Ms. Kylie Jimenez | Chief People Officer & Member of Management Board | 1976 |
| Ms. Lisa Birringer | Senior Vice President of Global Financial Reporting & Accounting | — |
| Mr. Douglas Maffei Ph.D. | Vice President of Strategy & Investor Relations | — |
| Jasmina Alatovic | Vice President Corporate Communications | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 44.02
- MACD 12/26/9
- -1.81
- EMA 9 of MACD
- -2.08
- MACD histogram
- 0.27
- SMA 50
- $93.80
- Price below SMA 50
- EMA 50
- $92.15
- Price below EMA 50
- SMA 200
- $96.05
- Price below SMA 200
- EMA 200
- $95.93
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $105.00
- Average
- $116.14
- High
- $132.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +40.4 | -22.9 | ||||||||||
| 2022 | -25.8 | -16.0 | +16.2 | -22.4 | +11.9 | -7.7 | +4.9 | -11.5 | -8.7 | +0.7 | +15.9 | -11.4 |
| 2023 | -3.5 | -9.1 | -2.3 | -11.8 | -6.2 | +3.7 | +1.0 | +12.9 | -10.8 | -17.0 | +7.4 | +6.2 |
| 2024 | -15.4 | -5.9 | +1.4 | -4.6 | +11.8 | -21.9 | +9.3 | +9.3 | +35.0 | -5.7 | +6.2 | -2.8 |
| 2025 | +7.3 | -5.8 | -18.4 | +15.4 | -6.5 | -5.9 | -0.0 | -6.8 | -2.0 | +1.7 | -0.8 | -2.2 |
| 2026 | +17.6 | +1.2 | -17.3 | +15.7 | -1.6 | +1.5 | -3.6 | +10.1 | -3.6 | -9.0 | -0.4 |
Corporate actions
Upcoming
No upcoming corporate actions for BNTX
